Literature DB >> 21834681

The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.

Mariana N L Oliveira1, Jefferson P Hemerly, André U Bastos, Rosana Tamanaha, Flavia R M Latini, Cléber P Camacho, Anelise Impellizzeri, Rui M B Maciel, Janete M Cerutti.   

Abstract

BACKGROUND: We have previously described a p.G533C substitution in the rearranged during transfection (RET) oncogene in a large family with medullary thyroid carcinoma. Here, we explore the functional transforming potential of RET p.G533C mutation.
METHODS: Plasmids expressing RET mutants (p.G533C and p.C634Y) and RET wild type were stable transfected into a rat thyroid cell line (PCCL3). Biological and biochemical effects of RET p.G533C were investigated both in vitro and in vivo. Moreover, we report the first case of pheochromocytoma among the RET p.G533C-carriers in this Brazilian family and explore the RET mutational status in DNA isolated from pheochromocytoma.
RESULTS: Ectopic expression of RET p.G533C and p.C634Y activates RET/MAPK/ERK pathway at similar levels and significantly increased cell proliferation, compared with RET wild type. We additionally show that p.G533C increased cell viability, anchorage-independent growth, and micronuclei formation while reducing apoptosis, hallmarks of the malignant phenotype. RET p.G533C down-regulates the expression of thyroid specific genes in PCCL3. Moreover, RET p.G533C-expressing cells were able to induce liver metastasis in nude mice. Finally, we described two novel RET variants (G548V and S556T) in the DNA isolated from pheochromocytoma while they were absent in the DNA isolated from blood.
CONCLUSIONS: Our in vitro and in vivo analysis indicates that this mutation confers a malignant phenotype to PCCL3 cells. These findings, in association with the report of first case of pheochromocytoma in the Brazilian kindred, suggest that this noncysteine mutation may be more aggressive than was initially considered.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21834681     DOI: 10.1089/thy.2010.0190

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 3.  Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.

Authors:  Samuel A Wells
Journal:  Endocr Relat Cancer       Date:  2017-11-15       Impact factor: 5.678

Review 4.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

5.  Advances in Detecting Low Prevalence Somatic TERT Promoter Mutations in Papillary Thyroid Carcinoma.

Authors:  Vitor Rodrigues da Costa; Larissa Valdemarin Bim; Luiza Dornelles Penteado Pacheco E Silva; Gabriel Avelar Colloza-Gama; André Uchimura Bastos; Rosana Delcelo; Gisele Oler; Janete Maria Cerutti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

6.  Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families.

Authors:  F O F Valente; M R Dias da Silva; C P Camacho; I S Kunii; A U Bastos; C C N da Fonseca; H P C Simião; R Tamanaha; R M B Maciel; J M Cerutti
Journal:  J Endocrinol Invest       Date:  2013-05-30       Impact factor: 4.256

7.  First reported case in Ireland of MEN2A due to a rare mutation in exon 8 of the RET oncogene.

Authors:  R Casey; S Prendeville; C Joyce; D O'Halloran
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-09-16

8.  Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.

Authors:  Larissa V Bim; Fábio C P Navarro; Flávia O F Valente; José V Lima-Junior; Rosana Delcelo; Magnus R Dias-da-Silva; Rui M B Maciel; Pedro A F Galante; Janete M Cerutti
Journal:  BMC Med Genomics       Date:  2019-07-09       Impact factor: 3.063

9.  LIMD2 Regulates Key Steps of Metastasis Cascade in Papillary Thyroid Cancer Cells via MAPK Crosstalk.

Authors:  Rodrigo Pinheiro Araldi; Thatiana Correa de Melo; Débora Levy; Dener Madeiro de Souza; Beatriz Maurício; Gabriel Avelar Colozza-Gama; Sergio Paulo Bydlowski; Hongzhuang Peng; Frank J Rauscher; Janete Maria Cerutti
Journal:  Cells       Date:  2020-11-23       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.